…[T]he pharmaceuticals and biotechnology sector faces challenges on a number of levels…Pharma groups are also having to get to grips with the increasing globalisation of their markets…As a result, those companies that are dealing with the problems of access to medicine are well placed to profit from the rise of [emerging] markets, says Ms Menou of Innovest. She cites Glaxo and Novartis as being noted for research into neglected diseases such as malaria and tuberculosis while those two companies, as well as Merck and Roche are known for policies on differential pricing of drugs for emerging markets. "With the emergence of the middle classes in these markets, it is important to have relationships already in place in these countries," she adds.